Production (Stage)
Knight Therapeutics Inc.
GUD.TO
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -11.31% | 2.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.31% | 2.29% | |||
| Cost of Revenue | -8.16% | 16.54% | |||
| Gross Profit | -15.72% | -12.66% | |||
| SG&A Expenses | 0.72% | -3.20% | |||
| Depreciation & Amortization | -13.07% | -7.35% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.53% | 9.21% | |||
| Operating Income | -82.46% | -190.04% | |||
| Income Before Tax | -104.94% | 1,161.93% | |||
| Income Tax Expenses | 11.87% | -632.75% | |||
| Earnings from Continuing Operations | -80.15% | 12,209.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -80.15% | 12,209.47% | |||
| EBIT | -82.46% | -190.04% | |||
| EBITDA | -8.71% | -62.06% | |||
| EPS Basic | -79.95% | 12,616.67% | |||
| Normalized Basic EPS | -100.13% | 3,425.00% | |||
| EPS Diluted | -80.61% | 11,850.00% | |||
| Normalized Diluted EPS | -100.13% | 3,412.50% | |||
| Average Basic Shares Outstanding | -0.89% | -0.59% | |||
| Average Diluted Shares Outstanding | -0.86% | -0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||